The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs

被引:33
|
作者
Zhang, Yuan [1 ]
Feng, Yang-Chun [2 ]
Zhu, Hong-Ge [3 ]
Xiong, Ting-Chuan [4 ]
Hou, Yan-Shen [5 ]
Song, Jia [1 ]
Jiang, Wei [6 ,7 ]
Zhu, Chang-Jun [8 ,9 ]
机构
[1] Xinjiang Med Univ, Affiliated Tumor Hosp, Dept Canc Researcher Inst, Urumqi, Peoples R China
[2] Xinjiang Med Univ, Affiliated Tumor Hosp, Clin Lab Ctr, Urumqi, Peoples R China
[3] Xinjiang Med Univ, Affiliated Tumor Hosp, Dept Pulm Med 2, Urumqi, Peoples R China
[4] Xinjiang Med Univ, Affiliated Tumor Hosp, Dept Gynecol Surg, Urumqi, Peoples R China
[5] Xinjiang Med Univ, Affiliated Tumor Hosp, Dept Anesthesiol, Urumqi, Peoples R China
[6] Chinese Acad Med Sci, State Key Lab Mol Oncol, Canc Inst & Hosp, Beijing, Peoples R China
[7] Peking Union Med Coll, Beijing 100021, Peoples R China
[8] Tianjin Normal Univ, Tianjin Key Lab Anim & Plant Resistance, Coll Life Sci, Tianjin 300387, Peoples R China
[9] Tianjin Normal Univ, Key Lab Mol & Cellular Syst Biol, Tianjin, Peoples R China
关键词
epidermal growth factor receptor; lymphocyte-to-monocyte ratio; neutrophil-to-lymphocyte ratio; nonsmall cell lung cancer; tyrosine kinase inhibitors; TYROSINE KINASE INHIBITORS; CLINICAL-OUTCOMES; CARCINOMA; IMMUNITY; INNATE; TUMORS;
D O I
10.1097/MD.0000000000011648
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line treatment for EGFR-mutant nonsmall cell lung cancer (NSCLC) patients. However, studies have reported that not all NSCLC patients harboring kinase domain mutations in epidermal growth factor receptor (EGFR) show significant clinical benefits from EGFR-targeted tyrosine kinase inhibitors (TKIs). Therefore, it is necessary to establish feasible biomarkers to predict the prognosis of EGFR-mutant NSCLC patients treated with EGFR-TKIs. This study aimed to determine biomarkers using inflammatory parameters from complete blood counts to predict the prognosis of EGFR-mutant NSCLC patients treated with EGFR-TKIs.We retrospectively investigated 127 stage IIIB/IV NSCLC patients with activating EGFR mutations who were treated with EGFR-TKIs. We used receiver operating characteristic (ROC) curves to determine the optimal cut-off for the inflammatory markers as prognostic factors. Additionally, univariate and multivariate analyses were used to identify prognostic factors for progression-free survival (PFS) and overall survival (OS) of EGFR-mutant NSCLC patients treated with EGFR-TKIs.The receiver operating characteristic analysis indicated that the lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) cut-off values were 3.37 and 2.90, respectively. The univariate analysis showed that a high LMR (>3.37) and low NLR (2.90) were significantly correlated with long-term PFS and OS (LMR, P=.007; NLR, P<.001). The multivariate Cox regression analysis revealed that only low NLR was an independent prognostic factor for long-term PFS and OS (PFS, HR=0.573, 95% CI: 0.340-0.964, P=.036; OS, HR=0.491, 95% CI: 0.262-0.920, P=.026).The data show that a low NLR was a good prognostic factor in EGFR-mutant NSCLC patients receiving EGFR-TKIs treatment. Moreover, the NLR measurement has better prognostic value than LMR.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
    Lin, Jessica J.
    Cardarella, Stephanie
    Lydon, Christine A.
    Dahlberg, Suzanne E.
    Jackman, David M.
    Jaenne, Pasi A.
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : 556 - 565
  • [2] Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs
    Kuang, Linwu
    Zhang, Yuchen
    Wang, Hao
    Wang, Peng
    Li, Yangkai
    BMC PULMONARY MEDICINE, 2025, 25 (01):
  • [3] Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
    Mari Tone
    Kota Iwahori
    Takayuki Shiroyama
    Shinji Futami
    Yujiro Naito
    Kiyoharu Fukushima
    Kotaro Miyake
    Shohei Koyama
    Haruhiko Hirata
    Izumi Nagatomo
    Hisashi Wada
    Yoshito Takeda
    Atsushi Kumanogoh
    Scientific Reports, 13
  • [4] Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
    Tone, Mari
    Iwahori, Kota
    Shiroyama, Takayuki
    Futami, Shinji
    Naito, Yujiro
    Fukushima, Kiyoharu
    Miyake, Kotaro
    Koyama, Shohei
    Hirata, Haruhiko
    Nagatomo, Izumi
    Wada, Hisashi
    Takeda, Yoshito
    Kumanogoh, Atsushi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [5] Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer
    Xu, Cong
    Yao, Xiaojun
    Li, Ting
    Wang, Jue
    An, Bo
    Wang, Jing
    Sui, Xinbing
    Leung, Elaine Lai-Han
    Wu, Qibiao
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2875 - 2883
  • [6] Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
    Taihei Ono
    Satoshi Igawa
    Shintaro Kurahayashi
    Yuriko Okuma
    Ai Sugimoto
    Seiichiro Kusuhara
    Takahiro Ozawa
    Tomoya Fukui
    Jiichiro Sasaki
    Hisashi Mitsufuji
    Masanori Yokoba
    Masaru Kubota
    Masato Katagiri
    Katsuhiko Naoki
    Investigational New Drugs, 2020, 38 : 885 - 893
  • [7] Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
    Ono, Taihei
    Igawa, Satoshi
    Kurahayashi, Shintaro
    Okuma, Yuriko
    Sugimoto, Ai
    Kusuhara, Seiichiro
    Ozawa, Takahiro
    Fukui, Tomoya
    Sasaki, Jiichiro
    Mitsufuji, Hisashi
    Yokoba, Masanori
    Kubota, Masaru
    Katagiri, Masato
    Naoki, Katsuhiko
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 885 - 893
  • [8] Impact of Neutrophil-to-Lymphocyte Ratio in Patients with EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibitors
    Ono, T.
    Igawa, S.
    Yamada, K.
    Kameda, A.
    Oguri, A.
    Yamamoto, H.
    Manabe, H.
    Ozawa, T.
    Kusuhara, S.
    Kasajima, M.
    Kakegawa, M.
    Otani, S.
    Fukui, T.
    Sasaki, J.
    Naoki, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S610 - S610
  • [9] Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis
    Lv, Fangfang
    Sun, Liang
    Yang, Qiuping
    Pan, Zheng
    Zhang, Yuhua
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [10] The efficacy and safety of adding anlotinib in gradual progression on third-generation EGFR-TKIs for EGFR-mutant advanced nonsmall cell lung cancer
    Xiang, Hai
    Danna, Ding
    Xuefei, Chen
    Zhao, Jinkai
    Jin, Guangjun
    ANTI-CANCER DRUGS, 2024, 35 (05) : 433 - 439